{"id":19211,"date":"2022-10-07T17:28:57","date_gmt":"2022-10-07T11:58:57","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=19211"},"modified":"2022-11-03T15:35:22","modified_gmt":"2022-11-03T10:05:22","slug":"peripheral-t-cell-lymphoma-treatment-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market","title":{"rendered":"Peripheral T-cell Lymphoma Treatment Market: How are Pipeline Therapies Reshaping the Therapeutic Outlook?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a08910399d4c\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a08910399d4c\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market\/#Current_Peripheral_T-cell_Lymphoma_Treatment_Space\" >Current Peripheral T-cell Lymphoma Treatment Space<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market\/#Emerging_Therapies_for_Peripheral_T-cell_Lymphoma_Treatment\" >Emerging Therapies for Peripheral T-cell Lymphoma Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market\/#Expected_Roadblocks_in_the_Peripheral_T-cell_Lymphoma_Treatment_Market\" >Expected Roadblocks in the Peripheral T-cell Lymphoma Treatment Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market\/#What_Lies_Ahead_in_the_Peripheral_T-cell_Treatment_Market\" >What Lies Ahead in the Peripheral T-cell Treatment Market?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Peripheral T-cell Lymphoma (PTCL) is a diverse disorder category that accounts for <strong>10% to 15%<\/strong> of non-Hodgkin lymphomas. Most PTCL subtypes, including PTCL-NOS, AITL, ALCL, enteropathy-type T-cell lymphoma, and extranodal natural killer (NK) cell\/T-cell lymphoma, are aggressive (fast-growing) lymphomas.<\/p>\n\n\n\n<p>PTCLs are rare in the United States but more prevalent in Asia, Africa, and the Caribbean, probably as a result of infection to certain viruses such as the Epstein-Barr virus (EBV) and the human T-cell leukemia virus-1 (HTLV-1). PTCLs often afflict adults over 60; however, PTCLs are also diagnosed in young adults and children.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>As per DelveInsight analysis, the total <a href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-t-cell-lymphoma-epidemiology-forecast\">peripheral T-cell lymphoma incidence<\/a> in the 7MM was 18K in 2021, growing at a CAGR of 1.1% during the study period (2019\u20132032). United States accounted for 6.3K peripheral T-cell lymphoma incident cases in 2021.<\/strong><\/p><\/blockquote>\n\n\n\n<div contenteditable=\"false\"><div id=\"highcharts-5a3df38c-3ba9-4fd9-9b2d-25e390172bbd\"><svg aria-hidden=\"false\" aria-label=\"Interactive chart\" class=\"highcharts-root\" height=\"400\" style=\"font-family: &quot;Lucida Grande&quot;, &quot;Lucida Sans Unicode&quot;, Arial, Helvetica, sans-serif; font-size: 12px;\" version=\"1.1\" viewBox=\"0 0 509 400\" width=\"509\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"><desc aria-hidden=\"true\">Created with Highcharts 10.2.1<\/desc><defs aria-hidden=\"true\"><clipPath id=\"highcharts-uau86c3-634-\"><rect fill=\"none\" height=\"271\" width=\"438\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-uau86c3-638-\"><rect fill=\"none\" height=\"271\" width=\"438\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-uau86c3-639-\"><rect fill=\"none\" height=\"271\" width=\"438\" x=\"61\" y=\"92\"><\/rect><\/clipPath><\/defs><rect aria-hidden=\"true\" class=\"highcharts-background\" fill=\"#ffffff\" height=\"400\" rx=\"0\" ry=\"0\" width=\"509\" x=\"0\" y=\"0\"><\/rect><rect aria-hidden=\"true\" class=\"highcharts-plot-background\" fill=\"none\" height=\"271\" width=\"438\" x=\"61\" y=\"92\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-pane-group\" data-z-index=\"0\"><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-xaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 206.5 92 L 206.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 352.5 92 L 352.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 498.5 92 L 498.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 60.5 92 L 60.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-yaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 61 363.5 L 499 363.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 61 295.5 L 499 295.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 61 228.5 L 499 228.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 61 160.5 L 499 160.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 61 91.5 L 499 91.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><\/g><rect aria-hidden=\"true\" class=\"highcharts-plot-border\" data-z-index=\"1\" fill=\"none\" height=\"271\" width=\"438\" x=\"61\" y=\"92\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-xaxis\" data-z-index=\"2\"><path class=\"highcharts-axis-line\" d=\"M 61 363.5 L 499 363.5\" data-z-index=\"7\" fill=\"none\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-yaxis\" data-z-index=\"2\"><text class=\"highcharts-axis-title\" data-z-index=\"7\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0) rotate(270 26.40000009536743 227.5)\" x=\"26.40000009536743\" y=\"227.5\">total incident cases (in thousands)<\/text><path class=\"highcharts-axis-line\" d=\"M 61 92 L 61 363\" data-z-index=\"7\" fill=\"none\"><\/path><\/g><g aria-hidden=\"false\" class=\"highcharts-series-group\" data-z-index=\"3\"><g aria-hidden=\"false\" class=\"highcharts-series highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"url(#highcharts-uau86c3-638-)\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(61,92) scale(1 1)\"><rect aria-label=\"US, 6.3. Total Incident Cases (in thousands).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"213\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"71\" x=\"37.5\" y=\"58.5\"><\/rect><rect aria-label=\"EU5, 5. Total Incident Cases (in thousands).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"169\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"71\" x=\"183.5\" y=\"102.5\"><\/rect><rect aria-label=\"Japan, 6.6. Total Incident Cases (in thousands).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"224\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"71\" x=\"329.5\" y=\"47.5\"><\/rect><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(61,92) scale(1 1)\"><\/g><\/g><text aria-hidden=\"true\" class=\"highcharts-title\" data-z-index=\"4\" style=\"color: rgb(51, 51, 51); font-size: 18px; fill: rgb(51, 51, 51);\" text-anchor=\"middle\" x=\"255\" y=\"24\">Peripheral T-cell Lymphoma Epidemiological<tspan dy=\"21\" x=\"255\">\u200b<\/tspan>Insights (2021)<\/text><text aria-hidden=\"true\" class=\"highcharts-subtitle\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" x=\"255\" y=\"73\">Total PTCL Incident Cases in the 7MM<\/text><text aria-hidden=\"true\" class=\"highcharts-caption\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"start\" x=\"10\" y=\"397\"><\/text><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-0 highcharts-column-series highcharts-color-0\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(61,92) scale(1 1)\"><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(59,35)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">6.3<tspan dy=\"0\" x=\"5\">\u200b<\/tspan><\/tspan>6.3<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(210,79)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">5<tspan dy=\"0\" x=\"5\">\u200b<\/tspan><\/tspan>5<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(351,24)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">6.6<tspan dy=\"0\" x=\"5\">\u200b<\/tspan><\/tspan>6.6<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-xaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"134\" y=\"382\">US<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"280\" y=\"382\">EU5<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"426\" y=\"382\">Japan<\/text><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-yaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"46\" y=\"367\">0<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"46\" y=\"299\">2<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"46\" y=\"232\">4<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"46\" y=\"164\">6<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"46\" y=\"96\">8<\/text><\/g><text aria-hidden=\"false\" aria-label=\"Chart credits: Peripheral T-cell Lymphoma Epidemiology Forecast - 2032\" class=\"highcharts-credits\" data-z-index=\"8\" style=\"cursor: pointer; color: rgb(153, 153, 153); font-size: 9px; fill: rgb(153, 153, 153);\" text-anchor=\"end\" x=\"499\" y=\"395\">Peripheral T-cell Lymphoma Epidemiology Forecast &#8211; 2032<\/text><g aria-hidden=\"true\" class=\"highcharts-control-points\" clip-path=\"url(#highcharts-uau86c3-639-)\" data-z-index=\"99\"><\/g><\/svg><\/div><script>(function(){ var files = [\"https:\/\/code.highcharts.com\/stock\/highstock.js\",\"https:\/\/code.highcharts.com\/highcharts-more.js\",\"https:\/\/code.highcharts.com\/highcharts-3d.js\",\"https:\/\/code.highcharts.com\/modules\/data.js\",\"https:\/\/code.highcharts.com\/modules\/exporting.js\",\"https:\/\/code.highcharts.com\/modules\/funnel.js\",\"https:\/\/code.highcharts.com\/modules\/annotations.js\",\"https:\/\/code.highcharts.com\/modules\/accessibility.js\",\"https:\/\/code.highcharts.com\/modules\/solid-gauge.js\"],loaded = 0; if (typeof window[\"HighchartsEditor\"] === \"undefined\") {window.HighchartsEditor = {ondone: [cl],hasWrapped: false,hasLoaded: false};include(files[0]);} else {if (window.HighchartsEditor.hasLoaded) {cl();} else {window.HighchartsEditor.ondone.push(cl);}}function isScriptAlreadyIncluded(src){var scripts = document.getElementsByTagName(\"script\");for (var i = 0; i < scripts.length; i++) {if (scripts[i].hasAttribute(\"src\")) {if ((scripts[i].getAttribute(\"src\") || \"\").indexOf(src) >= 0 || (scripts[i].getAttribute(\"src\") === \"http:\/\/code.highcharts.com\/highcharts.js\" && src === \"https:\/\/code.highcharts.com\/stock\/highstock.js\")) {return true;}}}return false;}function check() {if (loaded === files.length) {for (var i = 0; i < window.HighchartsEditor.ondone.length; i++) {try {window.HighchartsEditor.ondone[i]();} catch(e) {console.error(e);}}window.HighchartsEditor.hasLoaded = true;}}function include(script) {function next() {++loaded;if (loaded < files.length) {include(files[loaded]);}check();}if (isScriptAlreadyIncluded(script)) {return next();}var sc=document.createElement(\"script\");sc.src = script;sc.type=\"text\/javascript\";sc.onload=function() { next(); };document.head.appendChild(sc);}function each(a, fn){if (typeof a.forEach !== \"undefined\"){a.forEach(fn);}else{for (var i = 0; i < a.length; i++){if (fn) {fn(a[i]);}}}}var inc = {},incl=[]; each(document.querySelectorAll(\"script\"), function(t) {inc[t.src.substr(0, t.src.indexOf(\"?\"))] = 1; }); function cl() {if(typeof window[\"Highcharts\"] !== \"undefined\"){var options={\"title\":{\"text\":\"Peripheral T-cell Lymphoma Epidemiological Insights (2021)\"},\"subtitle\":{\"text\":\"Total PTCL Incident Cases in the 7MM\"},\"exporting\":{},\"chart\":{\"type\":\"column\",\"polar\":false},\"plotOptions\":{\"series\":{\"dataLabels\":{\"enabled\":true},\"animation\":false}},\"series\":[{\"name\":\"Total Incident Cases (in thousands)\",\"turboThreshold\":0}],\"data\":{\"csv\":\"\\\"Column 1\\\";\\\"Total Incident Cases (in thousands)\\\"\\n\\\"US\\\";6.3\\n\\\"EU5\\\";5\\n\\\"Japan\\\";6.6\",\"googleSpreadsheetKey\":false,\"googleSpreadsheetWorksheet\":false},\"yAxis\":[{\"title\":{\"text\":\"total incident cases (in thousands)\"}}],\"legend\":{\"enabled\":false},\"credits\":{\"text\":\"Peripheral T-cell Lymphoma Epidemiology Forecast - 2032\",\"href\":\"https:\/\/www.delveinsight.com\/report-store\/peripheral-t-cell-lymphoma-epidemiology-forecast\"}};\/*\/\/ Sample of extending options:Highcharts.merge(true, options, {    chart: {        backgroundColor: \"#bada55\"    },    plotOptions: {        series: {            cursor: \"pointer\",            events: {                click: function(event) {                    alert(this.name + \" clicked\\n\" +                          \"Alt: \" + event.altKey + \"\\n\" +                          \"Control: \" + event.ctrlKey + \"\\n\" +                          \"Shift: \" + event.shiftKey + \"\\n\");                }            }        }    }});*\/new Highcharts.Chart(\"highcharts-5a3df38c-3ba9-4fd9-9b2d-25e390172bbd\", options);}}})();<\/script><\/div><p>&nbsp;<\/p>\n\n\n\n<p>Delveinsight also estimated that among EU-5, the highest cases of the incident population were found to be in Germany in 2021, followed by France. The least population with PTCL in 2021 was found to be in Spain.<\/p>\n\n\n\n<p>Patients with PTCL benefit from a treatment plan that is tailored to their specific symptoms, diagnosis, and reaction to various medications. When conservative peripheral T-cell lymphoma treatment options are used, many cases of PTCL resolve within a few weeks. This, however, is not the case for all patients. For other people, PTCL can persist considerably longer, even for months.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Current_Peripheral_T-cell_Lymphoma_Treatment_Space\"><\/span><strong>Current Peripheral T-cell Lymphoma Treatment Space<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The peripheral T-cell lymphoma treatment is aimed at curing the disease and includes the use of combination chemotherapy regimens, localized radiotherapy, stem cell transplants, and steroid treatment, among other things. It is usually treated with a combination of chemotherapies such as <strong>CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)<\/strong> and <strong>CHOEP or EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone)<\/strong>. In certain circumstances, a stem cell or bone marrow transplant is suggested after the completion of combined chemotherapy.<\/p>\n\n\n\n<p>The peripheral T-cell lymphoma treatment market currently offers supporting treatment choices such as <strong>conservative (nonsurgical) and surgical approaches<\/strong>. <strong>Physical therapy, behavioral treatments, and pharmaceutical therapies<\/strong> are also used in conservative peripheral T-cell lymphoma treatment.<\/p>\n\n\n\n<p>According to the analysis, <strong>80-90%<\/strong> of patients are cured with current peripheral T-cell lymphoma therapies (pain relievers, muscle relaxants, anti-inflammatories, antidepressants, calcium channel 2-ligands, epidural steroids, opioids, topical pain medications, physical therapy, and behavioral therapy) within 6-12 weeks or one year of PTCL treatment, which are considered the first line of treatment for <a href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-t-cell-lymphoma-epidemiology-forecast\">PTCL patients<\/a>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161935\/FDA-approved-Drugs-for-CTCL-1-1024x686.jpg\" alt=\"PTCL Drugs\" class=\"wp-image-19215\" width=\"1024\" height=\"686\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161935\/FDA-approved-Drugs-for-CTCL-1-1024x686.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161935\/FDA-approved-Drugs-for-CTCL-1-300x201.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161935\/FDA-approved-Drugs-for-CTCL-1-150x101.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161935\/FDA-approved-Drugs-for-CTCL-1-768x515.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161935\/FDA-approved-Drugs-for-CTCL-1-1536x1030.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161935\/FDA-approved-Drugs-for-CTCL-1-1568x1051.jpg 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161935\/FDA-approved-Drugs-for-CTCL-1.jpg 2041w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption><strong>Market Drugs for PTCL Treatment<\/strong><\/figcaption><\/figure>\n\n\n\n<p><strong>BELEODAQ (Belinostat, Acrotech Biopharma), ISTODAX (Romidepsin, Celgene), FOLOTYN (Pralatrexate, Acrotech Biopharma), ARRANON (Nelarabine, GlaxoSmithKline), and ADCETRIS (Brentuximab vedotin, Seattle Genetics)<\/strong> are among the FDA-approved peripheral T-cell lymphoma treatments.<\/p>\n\n\n\n<p>Apart from the approved PTCL therapies, there are also off-label therapies and additional new therapeutics for peripheral T-cell lymphoma treatment. Off-label therapy for relapsed peripheral T-cell lymphoma treatment that has been listed in the NCCN guidelines includes <strong>MabThera (<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/rituximab-biosimilars-insight\"><strong>Rituxan<\/strong><\/a><strong>), Bortezomib, Bendamustine, Lenalidomide, and Alemtuzumab.&nbsp;<\/strong><\/p>\n\n\n\n<p>Moreover, recently <a href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-t-cell-lymphoma-ptcl-market\">approved drugs for PTCL treatment<\/a> include <strong>XALKORI (crizotinib)<\/strong> by <strong>Pfizer<\/strong>, which was recently approved in 2021 for children patients 1 year and older and young adults with relapsed or refractory, systemic ALK-positive ALCL, and <strong>HIYASTA (tucidinostat)<\/strong> by <strong>HUYA Bioscience International<\/strong>. Furthermore, the <strong>Japanese Pharmaceuticals and Medical Devices Agency<\/strong> approved <strong>HBI-8000 monotherapy<\/strong> for relapsed or refractory (R\/R) ATL on June 23, 2021.<\/p>\n\n\n\n<p>Additionally, <strong>Eisai <\/strong>recently announced in March 2021 that it had obtained manufacturing and marketing approval in Japan for the anticancer agent <strong>\u201cRemitoro for intravenous drip infusion 300g\u201d (denileukin diftitox (genetic recombinant))<\/strong> with the indications of relapsed or refractory (r\/r) peripheral T-cell lymphoma and r\/r cutaneous T-cell lymphoma. Moreover, on May 19, 2021, <strong>REMITORO<\/strong> was added to Japan\u2019s <strong>National Health Insurance Drug Price List<\/strong>.<\/p>\n\n\n\n<p>Another drug <strong>DARVIAS (darinaparsin), <\/strong>developed by <strong>Solasia Pharma<\/strong>, was recently approved by the MHLW for relapsed or refractory PTCL in June 2022. Furthermore, the company reported that <strong>DARVIAS Injection<\/strong> was launched in Japan on August 22, 2022, for relapsed or refractory <a href=\"https:\/\/www.delveinsight.com\/infographics\/peripheral-t-cell-lymphoma-ptcl-market\">peripheral T-cell lymphoma treatment<\/a>.&nbsp;<\/p>\n\n\n\n<p>However, one of the most difficult challenges for novel therapies is the capacity to conduct robust clinical studies in rare diseases. Leaving aside these difficulties, recent advances in understanding the biology and pathology of PTCL have resulted in the development of novel therapies.<\/p>\n\n\n\n<p>With the new insights into understanding PTCL, future efforts for PTCL treatment should focus on establishing trials customized for distinct subtypes and investigating innovative combination treatments in the front-line scenario.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Emerging_Therapies_for_Peripheral_T-cell_Lymphoma_Treatment\"><\/span><strong>Emerging Therapies for Peripheral T-cell Lymphoma Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-t-cell-lymphomas-ptcl-pipeline-insight\">peripheral T-cell lymphoma pipeline<\/a> possesses potential drugs in the mid-stage of development and are expected to be launched in the coming years. Presently, leading companies such as <strong>Viracta Therapeutics, Dizal Pharmaceuticals, Daiichi Sankyo, CStone Pharmaceuticals, Rhizen Pharmaceuticals, Kura Oncology, BeiGene, Celgene Corporation, Innate Pharma, Otsuka Pharmaceutical, Astex Pharmaceuticals, Merck Sharp &amp; Dohme Corp., Bristol Myers Squibb, Affimed, AstraZeneca<\/strong>, and others are working in the domain and will create a significant positive shift in PTCL market size in the future.<\/p>\n\n\n\n<p>Additionally, various emerging therapies are being evaluated in clinical trials for peripheral T-cell lymphoma treatment and its subtypes. The emerging peripheral T-cell lymphoma therapies include <strong>Nanatinostat + Valganciclovir, COPIKTRA, Tolinapant, Valemetostat, AZD4573<\/strong>, and others.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/peripheral-t-cell-lymphomas-ptcl-pipeline-insight\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07162008\/PTCL-Pipeline-Assessment-1024x421.jpg\" alt=\"PTCL Pipeline\" class=\"wp-image-19216\" width=\"1024\" height=\"421\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07162008\/PTCL-Pipeline-Assessment-1024x421.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07162008\/PTCL-Pipeline-Assessment-300x123.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07162008\/PTCL-Pipeline-Assessment-150x62.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07162008\/PTCL-Pipeline-Assessment-768x316.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07162008\/PTCL-Pipeline-Assessment-1536x632.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07162008\/PTCL-Pipeline-Assessment-1568x645.jpg 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07162008\/PTCL-Pipeline-Assessment.jpg 2041w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p><strong>Viracta Therapeutics<\/strong> is developing <strong>nanatinostat<\/strong>, an orally accessible histone deacetylase (HDAC) inhibitor. It is selective for certain isoforms of Class I HDACs, which is important for activating viral genes that are epigenetically repressed in Epstein-Barr virus (EBV)-associated cancers. Multiple PTCL clinical trials are now underway to examine the effectiveness of nanatinostat with valganciclovir in patients with relapsed\/refractory EBV + malignancies. Currently, nanatinostat is being studied in conjunction with the antiviral drug valganciclovir as an all-oral combination treatment in multiple subtypes of EBV-associated cancers.<\/p>\n\n\n\n<p>Ongoing trials include a pivotal, global, multicenter, open-label <strong>Phase II basket study<\/strong> in several subtypes of relapsed\/refractory EBV+ lymphoma (NAVAL-1) and a multinational <strong>Phase Ib\/II trial<\/strong> in patients with EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid malignancies. The company believes <strong>NAVAL-1<\/strong> might support numerous NDA applications across diverse EBV+ lymphoma subtypes. The trial has sites open across the world, including the United States, Canada, Europe, and Asia. A report on the initial cohorts that may progress to Stage 2 of the study is expected in the fourth quarter of 2022.<\/p>\n\n\n\n<p><strong>Valemetostat<\/strong>, a potentially selective first-in-class dual inhibitor of EZH1 and EZH2, is now under clinical development in <strong>Daiichi Sankyo\u2019s<\/strong> alpha portfolio. <strong>Valemetostat <\/strong>is an epigenetic dysregulation inhibitor that targets the EZH1 and EZH2 enzymes. The company announced the NDA filing in Japan for <a href=\"https:\/\/www.delveinsight.com\/report-store\/adult-t-cell-leukemia-lymphoma-market\">adult T-cell leukemia\/lymphoma (ATL) patients<\/a> in 2021. Valemetostat\u2019s NDA filing in Japan is based on pivotal <strong>Phase II trial<\/strong> findings in Japanese patients with three aggressive subtypes of relapsed\/refractory ATL.&nbsp;<\/p>\n\n\n\n<p><strong>Secura Bio\u2019s COPIKTRA (Duvelisib)<\/strong> is a phosphoinositide 3-kinase inhibitor that is administered orally. The phosphoinositide 3-kinase (PI3K) signaling pathway is a major regulator of cancer proliferation (rapid expansion or spread) and metastasis (the development of new cancer growths distant from the initial site of cancer). Secura Bio stated that it had finished participation in the <strong>PRIMO trial<\/strong> in 2022. PRIMO has enrolled <strong>157<\/strong> participants in their study of COPIKTRA for relapsed or refractory (r\/r) peripheral T-cell lymphoma treatment in adult patients.<\/p>\n\n\n\n<p><strong>Tolinapant <\/strong>is a synthetic, small molecule developed by <strong>Astex Pharma<\/strong> that acts as a dual antagonist of cellular inhibitor of apoptosis protein (cIAP) 1 and X-linked inhibitor of apoptosis protein (XIAP) and has been shown in nonclinical models to have potent proapoptotic and tumor growth inhibitory activity. Tolinapant is now being tested in patients with PTCL and CTCL as part of <strong>Phase II<\/strong> research in patients with advanced solid tumors and lymphomas to establish safety, pharmacokinetics, and preliminary efficacy. <strong>Astex Pharmaceuticals<\/strong> announced in August 2020 that the US FDA had approved <strong>Tolinapant (previously ASTX660)<\/strong> for the treatment of T-cell lymphoma.<\/p>\n\n\n\n<p><strong>AstraZeneca\u2019s AZD4573<\/strong> is a Cyclin-dependent kinase 9 (CDK9) inhibitor that is a transcriptional regulator and a possible therapeutic target for several malignancies. Multiple nonselective CDK9 inhibitors have advanced in clinical trials but have been hampered by a restricted therapeutic window. AZD4573, a new, potent, and highly specific CDK9 inhibitor, is described in this study. The company reported in Q1 2022 that the first patient began dosing in Q1 2022, and the company anticipated <strong>Phase II<\/strong> results by 2023.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Expected_Roadblocks_in_the_Peripheral_T-cell_Lymphoma_Treatment_Market\"><\/span><strong>Expected Roadblocks in the Peripheral T-cell Lymphoma Treatment Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In comparison to the United States and Japan, Europe has a significant shortage of approved <a href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-t-cell-lymphomas-ptcl-pipeline-insight\">PTCL drugs<\/a>. The current therapies are ineffective, and forthcoming therapies in the peripheral T-cell lymphoma treatment market encounter challenges in clinical trials due to the small number of patients with rare variants of PTCL.<\/p>\n\n\n\n<p>Moreover, the high cost of new therapies may hinder their acceptance, particularly in cost-conscious economies undergoing austerity measures. Furthermore, diagnostic and treatment solutions are desperately needed in the peripheral T-cell lymphoma treatment market to enhance the prognosis of PTCL and patient outcomes in the future.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Lies_Ahead_in_the_Peripheral_T-cell_Treatment_Market\"><\/span><strong>What Lies Ahead in the Peripheral T-cell Treatment Market?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Efforts have been made in recent years to incorporate novel treatments into combination methods for treating this difficult disease type. The recent introduction of therapies such as <strong>HIYASTA, DRAVIAS, and REMITORO<\/strong> in Japan has expanded the PTCL market and addressed unmet patient needs.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>According to DelveInsight analysis, the total <a href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-t-cell-lymphoma-ptcl-market\">PTCL market size<\/a> in the 7MM is USD 564 million in 2021 and is projected to grow during the forecast period (2022\u20132032).<\/strong><\/p><\/blockquote>\n\n\n\n<p>The rapid change in the peripheral T-cell lymphoma treatment market is mainly attributed to the launch of <strong>Adcetris<\/strong>, along with the robust clinical pipeline and the upcoming launch of emerging therapies such as <strong>Azacitidine (CC-486) and COPIKTRA (Duvelisib)<\/strong> in the forecasted period (2022\u20132032).<\/p>\n\n\n\n<p>Furthermore, several other PTCL therapies in development right now look to be significantly more promising and less hazardous than the peripheral T-cell lymphoma treatments that are already accessible to patients. As there is no authorized therapy for CHOP-ineligible individuals, firms can turn their emphasis to this patient group in the coming years.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-t-cell-lymphoma-ptcl-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161707\/peripheral-t-cell-lymphoma-treatment-assessment-1024x256.png\" alt=\"PTCL Market Outlook\" class=\"wp-image-19214\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161707\/peripheral-t-cell-lymphoma-treatment-assessment-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161707\/peripheral-t-cell-lymphoma-treatment-assessment-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161707\/peripheral-t-cell-lymphoma-treatment-assessment-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161707\/peripheral-t-cell-lymphoma-treatment-assessment-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161707\/peripheral-t-cell-lymphoma-treatment-assessment-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161707\/peripheral-t-cell-lymphoma-treatment-assessment-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161707\/peripheral-t-cell-lymphoma-treatment-assessment.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-faqs\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1665138661686\"><strong class=\"schema-faq-question\"><strong>1. What is peripheral T-cell lymphoma?<\/strong><\/strong> <p class=\"schema-faq-answer\">PTCL is a kind of aggressive lymphoma that develops from mature T-cells and natural killer (NK) cells. It accounts for 10-15% of all non-Hodgkin lymphomas globally. The WHO categorization system identifies PTCL subtypes and divides the disorders into three categories: nodal, extranodal, and leukemic.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1665138677162\"><strong class=\"schema-faq-question\"><strong>2. What causes PTCL?<\/strong><\/strong> <p class=\"schema-faq-answer\">The exact peripheral T-cell lymphoma causes are unknown; however, it has been linked to Epstein-Barr virus (EBV) or human T-cell leukemia virus-1 exposure (HTLV-1).\u00a0<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1665138686392\"><strong class=\"schema-faq-question\"><strong>3. What are the peripheral T-cell lymphoma symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">The PTCL symptoms in the patients are similar to those seen in other aggressive lymphoid tumors.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1665138698870\"><strong class=\"schema-faq-question\"><strong>4. What are the current PTCL treatment options?<\/strong><\/strong> <p class=\"schema-faq-answer\">The current PTCL treatment consists of nonsurgical and surgical regimens, with the nonsurgical phase involving physical therapy and medicines. On the other hand, surgical protocols include various surgical operations such as discectomy or microdiscectomy, laminectomy, or laminotomy.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1665138711323\"><strong class=\"schema-faq-question\"><strong>5. What is the global peripheral T-cell lymphoma incidence?<\/strong><\/strong> <p class=\"schema-faq-answer\">The overall peripheral T-cell lymphoma incidence and frequency vary geographically. However, PTCL, in general, is more common in Asia and the Caribbean.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1665138724100\"><strong class=\"schema-faq-question\"><strong>6. What are the peripheral T-cell lymphoma survival rates?<\/strong><\/strong> <p class=\"schema-faq-answer\">Except for anaplastic lymphoma kinase-positive ALCL, most PTCL subtypes are aggressive lymphomas, including PTCL-NOS, AITL, ALCL, enteropathy-type T-cell lymphoma, and extranodal NK cell\/T-cell lymphoma, with 5-year survival rates of less than 30%.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1665138736467\"><strong class=\"schema-faq-question\"><strong>7. How many PTCL drugs are approved by the FDA?<\/strong><\/strong> <p class=\"schema-faq-answer\">BELEODAQ (Belinostat, Acrotech Biopharma), ISTODAX (Romidepsin, Celgene), FOLOTYN (Pralatrexate, Acrotech Biopharma), ARRANON (Nelarabine, GlaxoSmithKline), and ADCETRIS (Brentuximab vedotin, Seattle Genetics) are among the FDA-approved peripheral T-cell lymphoma treatments.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Peripheral T-cell Lymphoma (PTCL) is a diverse disorder category that accounts for 10% to 15% of non-Hodgkin lymphomas. Most PTCL subtypes, including PTCL-NOS, AITL, ALCL, enteropathy-type T-cell lymphoma, and extranodal natural killer (NK) cell\/T-cell lymphoma, are aggressive (fast-growing) lymphomas. PTCLs are rare in the United States but more prevalent in Asia, Africa, and the Caribbean, [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":19212,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[137,841,927,667,19269,19807],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-19211","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-cancer","tag-cancer-research","tag-cancer-treatment","tag-lymphoma","tag-t-cell-lymphoma","tag-t-cell-lymphoma-market","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Recent Developments in the Peripheral T-cell Lymphoma Treatment Market<\/title>\n<meta name=\"description\" content=\"The peripheral T-cell lymphoma treatment pipeline possesses potential drugs in mid-stage development and expected to launched in coming years.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Recent Developments in the Peripheral T-cell Lymphoma Treatment Market\" \/>\n<meta property=\"og:description\" content=\"The peripheral T-cell lymphoma treatment pipeline possesses potential drugs in mid-stage development and expected to launched in coming years.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-07T11:58:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-03T10:05:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161608\/peripheral-t-cell-lymphoma-treatment-market.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Recent Developments in the Peripheral T-cell Lymphoma Treatment Market","description":"The peripheral T-cell lymphoma treatment pipeline possesses potential drugs in mid-stage development and expected to launched in coming years.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market","og_locale":"en_US","og_type":"article","og_title":"Recent Developments in the Peripheral T-cell Lymphoma Treatment Market","og_description":"The peripheral T-cell lymphoma treatment pipeline possesses potential drugs in mid-stage development and expected to launched in coming years.","og_url":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-10-07T11:58:57+00:00","article_modified_time":"2022-11-03T10:05:22+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161608\/peripheral-t-cell-lymphoma-treatment-market.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market","url":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market","name":"Recent Developments in the Peripheral T-cell Lymphoma Treatment Market","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161608\/peripheral-t-cell-lymphoma-treatment-market.png","datePublished":"2022-10-07T11:58:57+00:00","dateModified":"2022-11-03T10:05:22+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The peripheral T-cell lymphoma treatment pipeline possesses potential drugs in mid-stage development and expected to launched in coming years.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138661686"},{"@id":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138677162"},{"@id":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138686392"},{"@id":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138698870"},{"@id":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138711323"},{"@id":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138724100"},{"@id":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138736467"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161608\/peripheral-t-cell-lymphoma-treatment-market.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161608\/peripheral-t-cell-lymphoma-treatment-market.png","width":772,"height":482,"caption":"peripheral-t-cell-lymphoma-treatment-market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138661686","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138661686","name":"1. What is peripheral T-cell lymphoma?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"PTCL is a kind of aggressive lymphoma that develops from mature T-cells and natural killer (NK) cells. It accounts for 10-15% of all non-Hodgkin lymphomas globally. The WHO categorization system identifies PTCL subtypes and divides the disorders into three categories: nodal, extranodal, and leukemic.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138677162","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138677162","name":"2. What causes PTCL?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The exact peripheral T-cell lymphoma causes are unknown; however, it has been linked to Epstein-Barr virus (EBV) or human T-cell leukemia virus-1 exposure (HTLV-1).\u00a0","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138686392","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138686392","name":"3. What are the peripheral T-cell lymphoma symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The PTCL symptoms in the patients are similar to those seen in other aggressive lymphoid tumors.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138698870","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138698870","name":"4. What are the current PTCL treatment options?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The current PTCL treatment consists of nonsurgical and surgical regimens, with the nonsurgical phase involving physical therapy and medicines. On the other hand, surgical protocols include various surgical operations such as discectomy or microdiscectomy, laminectomy, or laminotomy.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138711323","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138711323","name":"5. What is the global peripheral T-cell lymphoma incidence?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The overall peripheral T-cell lymphoma incidence and frequency vary geographically. However, PTCL, in general, is more common in Asia and the Caribbean.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138724100","position":6,"url":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138724100","name":"6. What are the peripheral T-cell lymphoma survival rates?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Except for anaplastic lymphoma kinase-positive ALCL, most PTCL subtypes are aggressive lymphomas, including PTCL-NOS, AITL, ALCL, enteropathy-type T-cell lymphoma, and extranodal NK cell\/T-cell lymphoma, with 5-year survival rates of less than 30%.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138736467","position":7,"url":"https:\/\/www.delveinsight.com\/blog\/peripheral-t-cell-lymphoma-treatment-market#faq-question-1665138736467","name":"7. How many PTCL drugs are approved by the FDA?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"BELEODAQ (Belinostat, Acrotech Biopharma), ISTODAX (Romidepsin, Celgene), FOLOTYN (Pralatrexate, Acrotech Biopharma), ARRANON (Nelarabine, GlaxoSmithKline), and ADCETRIS (Brentuximab vedotin, Seattle Genetics) are among the FDA-approved peripheral T-cell lymphoma treatments.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/07161608\/peripheral-t-cell-lymphoma-treatment-market-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cancer research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cancer Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">T Cell Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">T Cell Lymphoma Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cancer research<\/span>","<span class=\"advgb-post-tax-term\">Cancer Treatment<\/span>","<span class=\"advgb-post-tax-term\">lymphoma<\/span>","<span class=\"advgb-post-tax-term\">T Cell Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">T Cell Lymphoma Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Oct 7, 2022","modified":"Updated on Nov 3, 2022"},"absolute_dates_time":{"created":"Posted on Oct 7, 2022 5:28 pm","modified":"Updated on Nov 3, 2022 3:35 pm"},"featured_img_caption":"peripheral-t-cell-lymphoma-treatment-market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19211","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=19211"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19211\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/19212"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=19211"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=19211"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=19211"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=19211"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=19211"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}